Cointime

Entasis Therapeutics

company

About

Entasis Therapeutics is developing a portfolio of innovative cures.

  • 1 - 10

Highlights

Total Funding Amount
$31.90M
Funding Rounds
1
Investors
1

Details

Last Funding Type
Series B
Last Funding Money Raised
$31.90M
Industries
Biotechnology,Health Care,Medical,Pharmaceutical
Founded date
Jan 1, 2015
Number Of Employee
1 - 10
Operating Status
Active

Entasis Therapeutics is developing a portfolio of innovative cures for serious drug-resistant bacterial infections, a global health crisis affecting the lives of millions of patients. Entasis’ anti-infective discovery platform has produced a pipeline of meaningfully differentiated programs which target serious bacterial infections, including ETX2514SUL (targeting Acinetobacter baumannii infections), ETX0282CPDP (targeting Enterobacteriaceae infections), and zoliflodacin (targeting Neisseria gonorrhoeae).

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$31.90M
Entasis Therapeutics has raised a total of $31.90M in funding over 2 rounds. Their latest funding was raised on Sep 5, 2017 from a Series B round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Sep 5, 2017 Series B $31.90M 1 — — Detail

Investors

Number of Lead Investors
Number of Investors
—
1
Entasis Therapeutics is funded by 1 investors. TPG are the most recent investors.
Investor Name Lead Investor Funding Round
TPG — Series B
Cointime
Content
Company